Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg-Reference-Cited by-同舟云学术

Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg

Published:2024-01-25 Issue:4 Volume:29 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Ernst Corinna¹²^ORCID,Bejko Dritan²,Gaasch Leo³,Hannelas Emilie³,Kahn Isaline³,Pierron Charlotte³,Del Lero Nesrine³,Schalbar Claude³,Do Carmo Elsa³,Kohnen Michel⁴,Andlauer Emmanuelle⁵,Hublart Pauline²,Masi Silvana²,de la Fuente Garcia Isabel³,Vergison Anne²,Mossong Joël²^ORCID

Affiliation:

1. ECDC Fellowship Programme, Field Epidemiology path (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

2. Health Directorate, Luxembourg

3. National Center for Pediatrics, Centre Hospitalier de Luxembourg, Luxembourg

4. Microbiology department, Centre Hospitalier de Luxembourg, Luxembourg

5. Hospital Pharmacy department, Centre Hospitalier de Luxembourg, Luxembourg

Abstract

After Luxembourg introduced nirsevimab immunisation against respiratory syncytial virus (RSV), estimated neonatal coverage was 84% (1,277 doses/1,524 births) in 2023. That year, paediatric RSV-related hospitalisations, especially concerning infants < 6 months old (n = 72) seemed to decrease compared to the same period in 2022 (n = 232). In 2023, hospitalised children’s mean age increased (14.4 months vs 7.8 months in 2022; p < 0.001) and hospital-stay length decreased (3.2 days vs 5.1 days; p < 0.001). In infants < 6 months old, intensive-care unit admissions appeared to drop (n = 28 vs 9). This suggests that nirsevimab prophylaxis reduced severe RSV infections, particularly in infants < 6 months old, thereby alleviating healthcare strain.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference11 articles.

1. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.;Li;Lancet,2022

2. Early and intense epidemic of respiratory syncytial virus (RSV) in Denmark, August to December 2022.;Munkstrup;Euro Surveill,2023

3. Respiratory syncytial virus infections - recent developments providing promising new tools for disease prevention.;Broberg;Euro Surveill,2023

4. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.;Drysdale;N Engl J Med,2023

5. Nirsevimab for prevention of RSV in healthy late-preterm and term infants.;Hammitt;N Engl J Med,2022